Switzerland-based Tillotts Pharma, part of the Japanese Zeria Group (TYO: 4559), has announced that Karima Boubekeur is joining the company to take on the newly-created role of global head of innovation.
Dr Boubekeur will lead the research and development (R&D) as well as the business development and licensing (BD&L) functions at Tillots, which specializes in gastroenterology and was taken over by Zeria in 2009.
Following Entocort's journey
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze